" class="no-js "lang="en-US"> Qurient Announces Clinical Study for Solid Tumors Treatments
Friday, March 31, 2023

Breaking News

NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions Sensorion Appoints Khalil Barrage as Interim Chairman of the Board Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China Hansa Biopharma Completes Enrollment in Phase 2 Study of Imlifidase in Guillain-Barré Syndrome (GBS) ProJenX Announces Formation of Scientific Advisory Board for Development of ALS Treatment NADclinic Group, BioStarks and Do Not Age Announce Exclusive Partnership to Revolutionise Personalised Longevity PathAI Announces Collaboration with GSK on NASH Phase 2b Clinical Trial Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors
Qurient Announces Dosing of First Patient in Clinical Study for the Treatment of Patients with Solid Tumors | PTF

January 31 2023

Qurient Announces Dosing of First Patient in Clinical Study for the Treatment of Patients with Solid Tumors

Qurient, a clinical-stage biotech company based in Korea, has announced that the first patient has been dosed in the Phase 1b/2 clinical study of Q702 in combination with KEYTRUDA® (pembrolizumab) for the treatment of patients with Solid Tumors.

The Q702 Phase 1b/2 study (NCT05438420) is being conducted at seven investigative sites in the U.S. and Korea, and approximately 142 patients with advanced solid tumors are scheduled to be enrolled. The primary objectives of the Phase 1b/2 study are to determine the safety and efficacy of Q702 in combination with KEYTRUDA in study subjects with advanced solid cancers.

“We are pleased to initiate evaluation of Q702 in combination with KEYTRUDA for the treatment of esophageal, gastric, hepatocellular, and cervical cancers, where limited immuno-oncology treatment options are currently available,” said Kiyean Nam, Ph.D., CEO of Qurient. “We have previously shown the potential additive benefit of Q702 in combination with anti-PD-1 therapy in preclinical models, and we expect the same clinical benefits of Q702 in combination with KEYTRUDA for patients.”

  1. NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business

    Drug Development

     Read more
  2. Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions

    Appointments

     Read more
  3. Sensorion Appoints Khalil Barrage as Interim Chairman of the Board

    Appointments

     Read more
  4. Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China

    Diseases

     Read more
  5. Hansa Biopharma Completes Enrollment in Phase 2 Study of Imlifidase in Guillain-Barré Syndrome (GBS)

    Clinical Trials

     Read more
More On